Cervical Smear Results ✅

🎯 Purpose of cervical screening: The NHS Cervical Screening Programme aims to prevent cervical cancer by detecting (1) high-risk HPV (hrHPV) infection and (2) precancerous cervical changes (CIN) in the transformation zone. Screening identifies high-risk individuals for treatment before invasive cancer develops. ⚠️ Screening is not a test for symptomatic disease—people with red-flag symptoms require urgent clinical assessment rather than waiting for routine screening.

🔍 Background & What the Programme Tests

• Primary hrHPV testing: All samples are first tested for hrHPV. Cytology (cell microscopy) is only performed if hrHPV is detected.
• Pathophysiology: Persistent hrHPV (especially types 16/18) expresses E6 and E7 oncoproteins → inactivation of p53 and Rb → dysregulated proliferation, genomic instability.
• Progression: CIN1 → CIN2 → CIN3 → invasive carcinoma if untreated over time.
• Primary HPV testing improves early detection and risk stratification.

🇬🇧 Screening Eligibility & Interval (England)

• Who is invited: Women and anyone with a cervix aged 25–64.
• First invite: ~24.5 years to allow screening from age 25.
• Routine interval: Every 5 years, unless hrHPV-positive or recent abnormal results → more frequent recall.

📊 Interpreting Results (Primary HPV Pathway)

1. HPV negative
   • ✅ Very low short–medium term risk of CIN3+/cancer.
   • 🔄 Routine recall at 5-year interval.
2. HPV positive + cytology abnormal
   • ⚠️ HPV detected and cell changes present → higher CIN2/3 risk.
   • ➡️ Refer for colposcopy for assessment and possible biopsy/treatment.
   • Cytology patterns:
     • Borderline / low-grade dyskaryosis → often CIN1, may regress.
     • High-grade dyskaryosis → often CIN2/3, usually treated.
     • Glandular abnormality or suspected invasion → urgent specialist referral.
3. HPV positive + cytology negative
   • 💡 Early or transient infection; low immediate risk.
   • 🔄 Repeat HPV testing at 12 months.
   • Persistent positivity → colposcopy referral per programme pathway.

🧬 Why Persistent HPV Matters

Most hrHPV infections clear spontaneously via cell-mediated immunity. Persistent hrHPV maintains oncoprotein expression, promoting CIN progression. Hence, the programme monitors HPV-positive/cytology-negative cases at defined intervals and escalates to colposcopy for persistent infection or abnormal cytology.

🩺 Management Principles (Colposcopy & Treatment)

• Colposcopy: Magnified visual assessment with acetic acid/iodine, directed biopsy of suspicious areas.
• CIN1: Observation/surveillance; treatment usually not immediate unless persistence or high-risk factors.
• CIN2/3: Excision of transformation zone (commonly LLETZ); aims to remove lesion and preserve cervical integrity.
• Test of Cure: ~6 months post-treatment; HPV testing ± cytology to ensure clearance.

🚨 Important: Symptoms Are NOT Screening

Screening is for asymptomatic individuals. If someone presents with concerning symptoms (e.g., post-menopausal bleeding, persistent abnormal discharge, pelvic pain), NICE NG12 recommends suspected cancer pathway referral rather than relying on routine screening results.

✨ Key Learning Points

• An abnormal screen ≠ cancer; it flags HPV or precancerous changes.
• Persistent hrHPV is the main driver for progression to CIN2/3.
• Primary HPV testing allows risk-stratified recall intervals.
• Test-of-cure at ~6 months post-treatment is essential to detect residual disease.
• HPV-negative individuals can safely return to standard recall intervals.

🧪 Example Cases (UK Programme Logic)

• Case 1 — HPV positive + borderline changes (age 28): Triggers colposcopy due to higher CIN2+ risk.
• Case 2 — HPV positive + cytology negative (age 34): Early/transient infection; repeat testing at 12 months. Persistent HPV → colposcopy.
• Case 3 — HPV positive + high-grade dyskaryosis (age 41): Urgent colposcopy with biopsy → confirmed CIN2/3 treated with LLETZ → test of cure at ~6 months.

📚 References (UK/NICE/NHS)

• UKHSA / GOV.UK: Cervical screening care pathway
• NICE CKS: Cervical screening — Management
• NHS: When you’ll be invited for cervical screening
• NHS England: Personalised cervical screening programme
• Cancer Research UK: What is cervical screening?
• NICE NG12: Suspected cancer: recognition and referral